ST天圣(002872) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥115,533,088.70, a decrease of 21.93% compared to ¥147,987,552.62 in the same period last year[5] - The net loss attributable to shareholders was ¥12,416,708.34, an improvement of 39.32% from a loss of ¥20,461,696.10 in the previous year[5] - Net profit for the period was a loss of ¥12,537,029.71, compared to a loss of ¥20,731,689.79 in the previous period, showing an improvement of approximately 40%[20] - The company reported a total asset of CNY 2,717,977,142.99 as of March 31, 2025, a slight decrease from CNY 2,736,124,198.16 at the beginning of the period[15] - Total operating revenue decreased to ¥115,533,088.70 from ¥147,987,552.62, a decline of approximately 22%[19] - Total operating costs reduced to ¥140,612,164.96 from ¥173,317,426.29, a decrease of about 19%[19] Cash Flow - The net cash flow from operating activities increased significantly by 831.46%, reaching ¥31,794,300.40 compared to ¥3,413,366.26 in the same period last year[5] - Cash flow from operating activities generated ¥31,794,300.40, significantly up from ¥3,413,366.26 in the previous period[21] - Cash flow from investment activities showed a net outflow of ¥5,598,162.05, an improvement from a net outflow of ¥12,308,817.04 in the previous period[21] - Net cash flow from financing activities was $1,431,099.46, a significant decrease from $106,889,610.07 in the previous period[22] - Cash inflows from financing activities totaled $93,300,000.00, down from $167,000,000.00 year-over-year[22] - Cash outflows for debt repayment amounted to $87,850,000.00, an increase from $56,100,000.00 in the previous period[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,717,977,142.99, a slight decrease of 0.66% from ¥2,736,124,198.16 at the end of the previous year[5] - Current assets totaled CNY 705,046,116.30, showing a marginal increase from CNY 702,436,533.60[15] - The total liabilities decreased slightly to CNY 716,326,000.35 from CNY 721,802,602.07, reflecting a reduction of about 0.8%[16] - The company's equity remained stable at CNY 1,400,779,329.86, unchanged from the previous period[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,396, with the largest shareholder holding 32.89% of the shares[10] - The company's weighted average return on equity was -0.62%, an improvement from -0.98% in the previous year[5] Research and Development - Research and development expenses rose by 42% year-on-year, driven by the advancement of new projects and drug re-registration[11] - Research and development expenses increased to ¥8,201,323.83 from ¥5,779,375.24, representing a rise of about 42%[19] Regulatory and Compliance - The company has not received any conclusive opinions or decisions from the China Securities Regulatory Commission regarding the ongoing investigation[14] - The company will actively cooperate with the regulatory body during the investigation period[14] - The company has not audited its first-quarter report for 2025[23] - The new accounting standards will be implemented starting in 2025[23] Other Financial Metrics - The company reported a decrease in accounts receivable from CNY 120,099,455.35 to CNY 94,754,796.53, a decline of approximately 21.1%[15] - The company’s inventory decreased from CNY 106,799,072.77 to CNY 100,225,778.99, a reduction of about 6.2%[15] - The company recorded a 244% increase in other income, primarily from a significant VAT refund received this period[11] - The company reported a decrease in sales expenses to ¥39,291,462.43 from ¥49,164,808.86, a reduction of approximately 20%[19] - The company recorded an investment loss of ¥558,811.98, contrasting with a gain of ¥35,587.88 in the previous period[19] - The basic and diluted earnings per share improved to -0.0390 from -0.0643, indicating a reduction in loss per share[20] - Cash and cash equivalents increased to CNY 294,493,873.46 from CNY 270,419,234.88, representing an increase of approximately 8.0%[15] - Short-term borrowings rose significantly to CNY 115,109,694.44 from CNY 80,080,055.56, indicating a 43.7% increase[16] - Other cash outflows related to financing activities were $425,000.00, down from $1,161,083.39 year-over-year[22]